-- 週一盤前，華爾街股指小幅走低，而原油價格上漲，交易員們正在權衡中東地區持續緊張局勢。 伊朗週六表示，為回應華盛頓拒絕解除海上封鎖，將再次關閉霍爾木茲海峽。 期貨方面，標普500指數、那斯達克指數和道瓊指數均較上週五收盤下跌約0.5%。 西德州中質原油價格上漲至每桶87.50美元，早盤漲幅達6%。 本週，投資人也將關注定於週二盤前在華盛頓公佈的3月份零售銷售數據，以及定於週四上午公佈的標普全球4月份綜合採購經理人指數（PMI）初值。 參議院銀行委員會將於週二上午就凱文沃什出任聯準會主席的提名舉行聽證會。 本週稍晚將公佈財報的藍籌股包括特斯拉 (TSLA)、英特爾 (INTC)、德州儀器 (TXN)、國際商業機器公司 (IBM)、聯合健康集團 (UNH)、通用電氣航空航天 (GE)、RTX (RTX)、洛克希德馬丁 (LMT)、波音 (BA)、AT&T (TAX) 和美國運通 (TAXP) 等。 亞洲股市隔夜普遍上漲，而歐洲股市午盤走低。 本週沒有經濟數據公佈。 盤前交易中，比特幣價格為 75,304 美元，10 年期美國公債殖利率為 4.26%。現貨黃金價格為每盎司 4,797 美元。
Related Articles
Asia
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
$KOSDAQ:440110
Asia
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.
$BOM:524715$NSE:SUNPHARMA